International Patent Landscape

European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400)

On April 3, 2019, the European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400) covering CRISPR-Cas9 systems, edited cells, and the use of CRISPR-Cas9 in any environment (including plant, animal and human cells). This third European patent also includes claims covering CRISPR-Cas9 compositions for use in […]

April 3, 2019
Read more Arrow right

“Europe: Legal issues lead to invalidation of second Broad patent; significant reduction in scope of third Broad patent”

EP2784162 (“EP’162”) & EP2896697 (“EP’697”): On February 15, 2019, the EPO revoked EP’162 in its entirety based on the same priority defect which EP’468 suffered. In addition, the EPO also revoked the original granted claims in EP’697, rejecting.35 sets of modified claims to arrive at an acceptable set of claims that are significantly narrower compared […]

February 15, 2019
Read more Arrow right

Europe: Doudna-Charpentier team awarded European patents

The EPO awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent covering the single-guide RNA format of the CRISPR-Cas9 system and its use in any environment (including plant, animal and human cells). This first European patent also includes claims covering the use of CRISPR-Cas9 in producing medicines for treating disease. Oppositions against this patent have been […]

March 9, 2018
Read more Arrow right

Australia: Broad patent awarded to Doudna-Charpentier team

Australia granted a broad patent to the Doudna-Charpentier team covering the single-guide RNA format of the CRISPR-Cas9 system and its use in any environment (including plant, animal and human cells). It also includes claims covering the use of CRISPR-Cas9 in producing medicines for treating disease.  

Read more Arrow right

UK: Patents granted to Doudna-Charpentier

The United Kingdom’s Intellectual Property Office awarded two patents to the Doudna-Charpentier team, with the first UK patent covering the single-guide RNA format of the CRISPR-Cas9 system and its use in any environment (including plant, animal and human cells). This patent also includes claims covering the use of CRISPR-Cas9 in producing medicines for treating disease. […]

March 9, 2018
Read more Arrow right

China: Patent granted to Doudna-Charpentier

In June 2017, China’s State Intellectual Property Office awarded a broad CRISPR-Cas9 patent to the Doudna-Charpentier team covering the single-guide RNA format of the CRISPR-Cas9 system and its use in any environment (including plant, animal and human cells). The Chinese patent also includes claims covering the use of CRISPR-Cas9 in producing medicines for treating disease. […]

Read more Arrow right

Europe: Legal issues lead to invalidation of Broad patent

The opposition system Under the European system, which covers 38 member countries through the European Patent Office (EPO), anyone can challenge the grant of a patent within nine months after issuance through a process known as an “opposition.” Opponents provide written arguments and evidence explaining why the patent should not have been granted, with opportunities […]

March 9, 2018
Read more Arrow right

Global: List of patents awarded to Doudna-Charpentier team

Patents have been granted to the Doudna-Charpentier team in a large number of countries worldwide, including: DATE LOCATION PATENT NUMBER 18 Jan 2016 Germany DE 202013012241 U1 2 Feb 2016 Germany DE 202013012240 U1 2 Feb 2016 Germany DE 202013012242 U1 2 Mar 2016 UK GB 2518764 C 03 Jun 2016 Tunisia 24223 8 Mar […]

Read more Arrow right